CRISPR Therapeutics: sell signal in observation
CRISPR Therapeutics stock: 3.1% bounce, but the decline is losing steam
CRISPR Therapeutics: sell signal in observation
Our view last week
CRISPR Therapeutics shares are slowing their slide: after two weeks of steep losses, this week's decline is just 2.6% and no new low was set. Signal strength drops to 46 out of 100, and this week's technical analysis shows sellers still dominant on the last bar, in a full distribution phase. The stock slips to 42nd among the 141 US sell signals: trading not recommended.
This week's summary
CRISPR Therapeutics stock closes the week with a 3.1% bounce, yet the sequence of lower highs on the daily chart — from the 60 area down to the 48 area — stays intact. It's the 3rd week of the Sell signal: strength drops to 6 out of 100, a decline losing steam, as seller dominance fades. This week's technical analysis places CRISPR Therapeutics 83rd among the 138 US sell signals: trading not recommended.
Sell signal in observation
·3rd week from start
·US stocks
·T2
·📅 Earnings · Aug 10
★ See Gold version →
IQS Phase
69
in tension
Signal Strength
6
decline losing steam
Sizing
MINIMUM
Ranking
#83 / 138
US stocks sell signals
Trade P&L %
-0.44%
from signal to date, no stop loss
Rank position
ranks 83rd among the 138 sell signals for US stocks in our ranking, with a signal strength of 6 out of 100.
Sector context
SectorHealth Care
Benchmark ETFXLV
Sector regimein positive regime
Performanceweekly -0.01% · monthly +1.89%
CRSP belongs to the health care sector (reference ETF XLV). The sector is classified in positive regime according to our weekly reading.
restricted Platinum content